Companies/HK/2269

药明生物 · WUXI BIOLOGICS (CAYMAN) INC.

Income flow

Annual
2269 10-K Income StatementPeriod 2025-12-31Source 10-K
Net salesHKD 22BRevenueHKD 22BGross profitHKD 10BCost of revenueHKD 12BOperating profitHKD 7BOperating expensesHKD 3BNet profitHKD 6BTaxHKD 825MOperating expensesHKD 3B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).4.12BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).3.71B
Stock splits
  1. 3:12020-11-16